Loading...
•
Jun 30, 2022
Fate Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported a revenue of $18.5 million for the second quarter of 2022, derived from collaborations with Janssen and ONO. The company's cash, cash equivalents, and investments totaled $580.8 million as of June 30, 2022. Research and development expenses were $81.3 million, while general and administrative expenses were $20.4 million for the same period.
FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL
FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL
First Patient Treated with FT536 iPSC-derived CAR MICA/B NK Cell Product Candidate for Solid Tumors
Commercial Option Exercised by Janssen for First Antigen Program; First IND Submission for CAR NK Cell Collaboration Product Planned for 2H22
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The company expects to submit its first IND application under the collaboration during the second half of 2022.